4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001567619-21-019331
EVP, Head of R&D sold 5,000 shares at $16.41 ($82,050)
- EVP, Head of R&D acquired 5,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dupont Jakob EVP, Head of R&D | 2021-11-02 | Option exercise | +5,000 | $9.58 | $47,900 | 97,793 | D |
| Dupont Jakob EVP, Head of R&D | 2021-11-02 | Sale | −5,000 | $16.41 | $82,050 | 92,793 | D |
| Derivatives | |||||||
| Dupont Jakob EVP, Head of R&D | 2021-11-02 | Option exercise · Employee Stock Option (Right to Buy) | −5,000 | 272,500 | D | ||
| Open-market sales · 5,000 sh · avg $16.41 · $82,050 | |||||||
Loading xslF345X03/doc1.xml…